Amphastar Pharmaceuticals Return on Investment 2012-2025 | AMPH
Current and historical return on investment (ROI) values for Amphastar Pharmaceuticals (AMPH) over the last 10 years.
| Amphastar Pharmaceuticals ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2025-12-31 | $0.14B | $1.38B | 10.18% |
| 2025-09-30 | $0.15B | $1.36B | 10.96% |
| 2025-06-30 | $0.18B | $1.35B | 13.46% |
| 2025-03-31 | $0.19B | $1.33B | 14.61% |
| 2024-12-31 | $0.21B | $1.31B | 15.70% |
| 2024-09-30 | $0.21B | $1.28B | 16.72% |
| 2024-06-30 | $0.23B | $1.26B | 18.30% |
| 2024-03-31 | $0.21B | $1.20B | 17.64% |
| 2023-12-31 | $0.20B | $1.04B | 18.94% |
| 2023-09-30 | $0.18B | $0.88B | 20.49% |
| 2023-06-30 | $0.13B | $0.72B | 18.20% |
| 2023-03-31 | $0.12B | $0.59B | 20.05% |
| 2022-12-31 | $0.11B | $0.58B | 18.73% |
| 2022-09-30 | $0.09B | $0.56B | 16.89% |
| 2022-06-30 | $0.10B | $0.54B | 17.84% |
| 2022-03-31 | $0.08B | $0.52B | 15.78% |
| 2021-12-31 | $0.07B | $0.50B | 13.95% |
| 2021-09-30 | $0.05B | $0.49B | 9.95% |
| 2021-06-30 | $0.03B | $0.49B | 5.75% |
| 2021-03-31 | $0.01B | $0.48B | 2.91% |
| 2020-12-31 | $0.01B | $0.48B | 2.31% |
| 2020-09-30 | $0.01B | $0.47B | 1.69% |
| 2020-06-30 | $0.01B | $0.47B | 1.28% |
| 2020-03-31 | $0.01B | $0.47B | 2.14% |
| 2019-12-31 | $0.00B | $0.46B | 0.00% |
| 2019-09-30 | $0.00B | $0.44B | 0.46% |
| 2019-06-30 | $0.00B | $0.41B | 0.73% |
| 2019-03-31 | $0.00B | $0.38B | -0.26% |
| 2018-12-31 | $-0.01B | $0.37B | -2.15% |
| 2018-09-30 | $-0.01B | $0.37B | -3.27% |
| 2018-06-30 | $-0.02B | $0.37B | -4.90% |
| 2018-03-31 | $-0.01B | $0.37B | -3.49% |
| 2017-12-31 | $0.00B | $0.37B | -0.54% |
| 2017-09-30 | $-0.01B | $0.37B | -1.37% |
| 2017-06-30 | $0.00B | $0.36B | 1.10% |
| 2017-03-31 | $0.01B | $0.36B | 3.38% |
| 2016-12-31 | $0.02B | $0.35B | 4.32% |
| 2016-09-30 | $0.03B | $0.34B | 10.04% |
| 2016-06-30 | $0.02B | $0.33B | 7.35% |
| 2016-03-31 | $0.00B | $0.32B | 1.24% |
| 2015-12-31 | $-0.01B | $0.32B | -2.19% |
| 2015-09-30 | $-0.03B | $0.32B | -8.83% |
| 2015-06-30 | $-0.03B | $0.32B | -10.02% |
| 2015-03-31 | $-0.02B | $0.32B | -7.14% |
| 2014-12-31 | $-0.02B | $0.31B | -5.83% |
| 2014-09-30 | $-0.01B | $0.30B | -2.72% |
| 2014-06-30 | $0.00B | $0.21B | 0.00% |
| 2014-03-31 | $0.01B | $0.13B | 9.94% |
| 2013-12-31 | $0.02B | $0.07B | 25.95% |
| 2013-09-30 | $0.07B | $0.06B | 106.02% |
| 2013-06-30 | $0.12B | $0.06B | 197.59% |
| 2013-03-31 | $0.16B | $0.06B | 257.03% |
| 2012-12-31 | $0.20B | $0.06B | 327.71% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |